Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Atzpodien

Showing results (51-60 of 116) with videos related to

Pageof 12
Sort By:
Experimental Cell Biology|January 1, 1987
Human bone marrow CFU-GM and BFU-E localized by light scatter cell sortingJ Atzpodien, S C Gulati, J H Kwon, et al.
Acta Haematologica|January 1, 1988
Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213C Shimazaki, S C Gulati, J Atzpodien, et al.
British Journal of Cancer|August 17, 2000
Capecitabine in the treatment of metastatic renal cell carcinomaK Oevermann, J Buer, R Hoffmann, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 1, 1997
Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinomaJ Buer, M Probst, S Duensing, et al.
Molecular Biotherapy|June 1, 1992
Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinomaA Schomburg, T Menzel, M Hadam, et al.
The Journal of Experimental Medicine|May 1, 1988
A transformation-associated 130-kD cell surface glycoprotein is growth controlled in normal human cellsC E Klein, H L Ozer, F Traganos, et al.
Natural Immunity|May 1, 1992
In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2A Schomburg, T Menzel, A Körfer, et al.
Molecular Biotherapy|June 1, 1991
Diminished expression of interleukin-2 receptors in vivo after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2J Atzpodien, A Körfer, M Hadam, et al.
Cancer Investigation|January 1, 1989
In vitro chemosensitivity of two Ewing's sarcoma cell lines: implication for autologous bone marrow transplantationS C Gulati, J H Kwon, J Atzpodien, et al.
Acta Haematologica|January 1, 1988
Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cellsC Shimazaki, J Atzpodien, D Wisniewski, et al.
Pageof 12

Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Experimental Cell Biology|January 1, 1987
Human bone marrow CFU-GM and BFU-E localized by light scatter cell sortingJ Atzpodien, S C Gulati, J H Kwon, et al.
Acta Haematologica|January 1, 1988
Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213C Shimazaki, S C Gulati, J Atzpodien, et al.
British Journal of Cancer|August 17, 2000
Capecitabine in the treatment of metastatic renal cell carcinomaK Oevermann, J Buer, R Hoffmann, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 1, 1997
Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinomaJ Buer, M Probst, S Duensing, et al.
Molecular Biotherapy|June 1, 1992
Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinomaA Schomburg, T Menzel, M Hadam, et al.
The Journal of Experimental Medicine|May 1, 1988
A transformation-associated 130-kD cell surface glycoprotein is growth controlled in normal human cellsC E Klein, H L Ozer, F Traganos, et al.
Natural Immunity|May 1, 1992
In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2A Schomburg, T Menzel, A Körfer, et al.
Molecular Biotherapy|June 1, 1991
Diminished expression of interleukin-2 receptors in vivo after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2J Atzpodien, A Körfer, M Hadam, et al.
Cancer Investigation|January 1, 1989
In vitro chemosensitivity of two Ewing's sarcoma cell lines: implication for autologous bone marrow transplantationS C Gulati, J H Kwon, J Atzpodien, et al.
Acta Haematologica|January 1, 1988
Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cellsC Shimazaki, J Atzpodien, D Wisniewski, et al.
Pageof 12